

Financial news for CORT dated on 2020-05-04: Corcept Therapeutics Q1 EPS \$0.340 Beats \$0.220 Estimate, Sales \$93.200M Beat \$87.010M Estimate

Financial news for CORT dated on 2020-05-04: Corcept Therapeutics Q1 Adj. EPS \$0.340 Beats \$0.220 Estimate, Sales \$93.200M Beat \$87.010M Estimate

Financial news for CORT dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for CORT dated on 2020-02-21: Cantor Fitzgerald Reiterates Neutral on Corcept Therapeutics, Raises Price Target to \$15

Financial news for CORT dated on 2020-02-20: 17 Stocks Moving In Thursday's After-Hours Session

Financial news for CORT dated on 2020-02-20: Corcept Therapeutics shares are trading higher after the company reported better-than-expected Q4 sales results. The company also reaffirmed FY20 sales guidance.

Financial news for CORT dated on 2020-02-20: Corcept Reaffirms FY20 Sales Guidance \$355M-\$375M

Financial news for CORT dated on 2020-02-20: Corcept Therapeutics Q4 EPS \$0.24 Misses \$0.25 Estimate, Sales \$87.9M Beat \$87.67M Estimate

Financial news for CORT dated on 2020-02-10: Corcept Therapeutics Wins IPR Patent Trial, PTAB Rules Neptune Generics Failed To Prove '348 Korlym Patent Claims Were Valid

Financial news for CORT dated on 2020-01-30: Corcept Therapeutics Q4 Sales \$87.9M Up From \$66.831M YoY

Financial news for CORT dated on 2019-11-21: 63 Biggest Movers From Yesterday

Financial news for CORT dated on 2019-11-20: Corcept Therapeutics Shares Resume Trade, Down 29.3%

Financial news for CORT dated on 2019-11-20: Corcept Therapeutics Shares Expected To Resume Trade At 3:24:23 p.m. EST

Financial news for CORT dated on 2019-11-20: Corcept Therapeutics Shares Halted On Circuit Breaker, Down 15.6% For Session

Financial news for CORT dated on 2019-11-20: Corcept Therapeutics Shares Fall As Hearing Teva Patent Trial Against Co.'s '214 Korlym Has Been Instituted By Patent Trial, Appeal Board As Patent Claims Determined to Be Likely Invalid

Financial news for CORT dated on 2019-11-07: Corcept Therapeutics Narrows FY19 Sales Guidance \$300M-\$315M

Financial news for CORT dated on 2019-11-07: Corcept Therapeutics Q3 EPS \$0.31 Beats \$0.2 Estimate, Sales \$81.505M Beat \$78M Estimate

Financial news for CORT dated on 2019-11-07: The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs

Financial news for CORT dated on 2019-09-24: Benzinga's Top Upgrades, Downgrades For September 24, 2019

Financial news for CORT dated on 2019-09-24: Jefferies Initiates Coverage On Corcept Therapeutics with Buy Rating, Announces \$20 Price Target

Financial news for CORT dated on 2019-09-06: Benzinga's Top Upgrades, Downgrades For September 6, 2019

Financial news for CORT dated on 2019-09-06: H.C. Wainwright Initiates Coverage On Corcept Therapeutics with Buy Rating, Announces \$18 Price Target

Financial news for CORT dated on 2019-08-28: Corcept Therapeutics Announces Allowance Of Additional Patent Covering The Use Of Korlym To Treat Patients With Cushing's Syndrome

Financial news for CORT dated on 2019-08-21: Hearing Corcept Therapeutics Has Received EU Orphan Drug Designation, Unconfirmed

Financial news for CORT dated on 2019-08-05: 82 Biggest Movers From Friday

Financial news for CORT dated on 2019-08-02: 60 Stocks Moving In Friday's Mid-Day Session

Financial news for CORT dated on 2019-08-01: Corcept Therapeutics Q2 EPS \$0.25 Beats \$0.18 Estimate, Sales \$72.257M Beat \$70.88M Estimate

Financial news for CORT dated on 2019-07-11: Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.

Financial news for CORT dated on 2019-06-11: Corcept Therapeutics 8-K Shows Co. Received Paragraph IV Notice Letter Advising Sun Pharma Submitted Abbreviated New Drug Application For FDA Authorization To Manufacture, Use Or Sell Generic Version Of KORLYM, 300mg In US

Financial news for CORT dated on 2019-06-01: The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace

Financial news for CORT dated on 2019-05-29: '\$CORT Corcept Therapeutics gets European Commission approval of Relacorilant for the treatment of Cushing's Syndrome.' -Tweets TradeHawk

Financial news for CORT dated on 2019-05-28: Corcept Therapeutics To Present Data From Phase 1/2 Trial Of Relacorilant Plus Nab-Paclitaxel In Patients With Solid Tumors At The American Society Of Clinical Oncology Annual Meeting

Financial news for CORT dated on 2019-05-10: Shares of several healthcare companies are trading lower in sympathy with the overall market. The S&P 500 is trading lower 1%

Financial news for CORT dated on 2019-05-09: Corcept Therapeutics Reaffirms FY2019 Sales Guidance from \$285M-315M to \$285M-315M

Financial news for CORT dated on 2019-05-09: Corcept Therapeutics Q1 EPS \$0.2 Beats \$0.19 Estimate, Sales \$64.8M Miss \$69.29M Estimate

Financial news for CORT dated on 2019-05-09: The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut

Financial news for CORT dated on 2019-05-02: Corcept Therapeutics Reports EMA Recommended Orphan Drug Designation For Relacorilant To Treat Patients With Cushing's Syndrome

Financial news for CORT dated on 2019-05-02: Corcept Therapeutics Announces European Medicines Agency Recommended Orphan Drug Designation For Relacorilant To Treat Patients With Cushing's Syndrome

Financial news for CORT dated on 2019-02-25: Corcept Therapeutics Q4 EPS \$0.24 Beats \$0.17 Estimate, Sales \$66.831M Miss \$69.32M Estimate

Financial news for CORT dated on 2019-02-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

Financial news for CORT dated on 2019-02-15: Hearing Corcept Therapeutics Lost IPR Patent Case For '348 Korlym Patent By Neptune Genetics; Unconfirmed

Financial news for CORT dated on 2019-02-07: Corcept's Korlym Patent Added To The FDA Orange Book

Financial news for CORT dated on 2019-02-05: Blue Orca Announces Corcept Therapeutics Short

Financial news for CORT dated on 2019-02-04: 60 Biggest Movers From Friday

Financial news for CORT dated on 2019-02-01: 45 Stocks Moving In Friday's Mid-Day Session

Financial news for CORT dated on 2019-02-01: 10 Biggest Price Target Changes For Friday

Financial news for CORT dated on 2019-02-01: The Daily Biotech Pulse: Merck Earnings, Positive Relaunch Of Titan's Opioid Disorder Treatment Implant

Financial news for CORT dated on 2019-02-01: Corcept shares are trading lower after the company said Q4 revenue will be worse than analysts expected.

Financial news for CORT dated on 2019-02-01: 35 Stocks Moving In Friday's Pre-Market Session

Financial news for CORT dated on 2019-02-01: Cantor Fitzgerald Downgrades Corcept

Therapeutics to Neutral, Lowers Price Target to \$14

Financial news for CORTE dated on 2019-01-31: Corcept Therapeutics Prelim. Q4 Sales \$66.8M Up From \$53.28M YoY

Financial news for CORTE dated on 2019-01-29: 24 Stocks Moving In Tuesday's Pre-Market Session

Financial news for CORTE dated on 2019-01-28: 55 Biggest Movers From Friday

Financial news for CORTE dated on 2019-01-25: UPDATE: Negative Call On Corcept Coming Out Of Roddy Boyd's SIFR 'Corcept Therapeutics: The Company That Perfectly Explains the Health Care Crisis'

Financial news for CORTE dated on 2019-01-25: Corcept Therapeutics Shares Fall 8% As Traders Circulate Word Of A Negative Call From Unnamed Source

Financial news for CORTE dated on 2018-12-30: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Financial news for CORTE dated on 2018-12-23: The Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial Results

Financial news for CORTE dated on 2018-12-13: Benzinga Pro's Top 10 Most-Searchd Tickers For Thurs., Dec. 13, 2018

Financial news for CORTE dated on 2018-12-13: Corcept Therapeutics Reports Allowance Of Added Patent Covering Use Of Korlym To Treat Patients With Cushing's Syndrome

Financial news for CORTE dated on 2018-12-12: Benzinga Pro's Top 10 Most-Searchd Tickers For Afternoon Of Wed., Dec. 12, 2018

Financial news for CORTE dated on 2018-12-12: 41 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CORTE dated on 2018-12-12: B. Riley FBR Sees Corcept Therapeutics Final Patent Issuance In Coming Weeks, Expects Patent To Protect Korlym Through 2037; Reiterates Buy, \$22 Price Target

Financial news for CORTE dated on 2018-12-12: 10 Biggest Price Target Changes For Wednesday

Financial news for CORTE dated on 2018-12-12: Benzinga's Top Upgrades, Downgrades For December 12, 2018

Financial news for CORTE dated on 2018-12-12: Corcept Therapeutics shares are continuing higher after receiving a patent for Krlym, which will give the company power over generic drug makers.

Financial news for CORTE dated on 2018-12-12: Cantor Fitzgerald Upgrades Corcept Therapeutics to Overweight, Raises Price Target to \$29

Financial news for CORTE dated on 2018-12-12: Hearing Cantor Fitzgerald Upgraded Corcept Therapeutics To Overweight With A \$29 Price Target; Unconfirmed

Financial news for CORTE dated on 2018-12-12: 48 Biggest Movers From Yesterday

Financial news for CORTE dated on 2018-12-11: Corcept Therapeutics Shares Spike ~18% Over Last Few Mins.; Traders Attributing Move To Vague Word Of Patent Approval

Financial news for CORTE dated on 2018-11-19: Corcept Therapeutics Announces First Patient Dosed In Phase 3 Trial Of Relacorilant To Treat Patients With Cushing's Syndrome

Financial news for CORTE dated on 2018-11-01: Corcept Therapeutics Q3 Adj. EPS \$0.22 Beats \$0.17 Estimate, Sales \$64.4M Miss \$67.41M Estimate

Financial news for CORTE dated on 2018-11-01: The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal

Financial news for CORTE dated on 2018-10-29: Stocks Which Set New 52-Week Low Friday, October 26th

Financial news for CORTE dated on 2018-10-25: The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price

Financial news for CORTE dated on 2018-10-24: Stocks Which Set New 52-Week Low Yesterday, October 23rd

Financial news for CORT dated on 2018-10-24: Judge Denies Teva Pharmaceuticals' Motion To Dismiss Corcept Therapeutics' Allegations Of Patent Infringement

Financial news for CORT dated on 2018-10-23: Corcept Therapeutics Shares Up 4% Over Last Few Mins. As Traders Circulate Court Order Doc Showing Teva Motion To Dismiss Co. Complaint Related To Generic Product Was Denied

Financial news for CORT dated on 2018-10-18: Corcept Therapeutics shares are ticking lower amid reports Teva has received tentative FDA approval for Mifepristone

Financial news for CORT dated on 2018-10-16: FDA Site Shows Orphan Drug Designation For Corcept Therapeutics' Relacorilant In The Treatment Of Endogenous Cushing Syndrome, Dated Oct. 15

Financial news for CORT dated on 2018-10-01: Corcept Therapeutics Reports Received Orphan Drug Designation For Relacorilant As Treatment For Pancreatic Cancer

Financial news for CORT dated on 2018-08-25: Insider Buys Of The Week: Andeavor, Corcept, Portola

Financial news for CORT dated on 2018-08-23: Cantor Fitzgerald Initiates Coverage On Corcept Therapeutics with Neutral Rating, Announces \$17 Price Target

Financial news for CORT dated on 2018-08-13: 61 Biggest Movers From Friday

Financial news for CORT dated on 2018-08-10: 60 Stocks Moving In Friday's Mid-Day Session

Financial news for CORT dated on 2018-08-10: Corcept Therapeutics shares are trading 10.7% lower following the company's quarterly earnings report. Earnings per share and sales both fell below analysts' estimates.

Financial news for CORT dated on 2018-08-10: 30 Stocks Moving In Friday's Pre-Market Session

Financial news for CORT dated on 2018-08-10: The Daily Biotech Pulse: Puma, CareDx Soar On Earnings, Corcept Plunges On Bottom-Line Miss

Financial news for CORT dated on 2018-08-09: 7 Stocks Moving In Thursday's After-Hours Session

Financial news for CORT dated on 2018-08-09: Corcept Therapeutics Q2 EPS \$0.20 Misses \$0.24 Estimate, Sales \$62.312M Miss \$68.5M Estimate

Financial news for CORT dated on 2018-06-21: Corcept Therapeutics Option Alert: Aug 17 \$12 Puts Sweep (36) near the Ask: 947 @ \$0.301 vs 26 OI; Earnings 7/31 After Close [est] Ref=\$16.49

Financial news for CORT dated on 2018-06-19: 60 Biggest Movers From Yesterday

Financial news for CORT dated on 2018-06-18: Corcept Therapeutics Option Alert: Aug 17 \$17 Puts Sweep (26) near the Ask: 600 @ \$1.101 vs 708 OI; Earnings 7/31 After Close [est] Ref=\$18.31

Financial news for CORT dated on 2018-06-03: The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines

Financial news for CORT dated on 2018-05-31: Corcept Therapeutics Shares Down 5.7% After Sitfel Earlier Downgraded To Hold; Firm Said Stock Is 'Fairly Valued'

Financial news for CORT dated on 2018-05-31: Corcept Therapeutics Is 'Fairly Valued,' Stifel Says In Downgrade

Financial news for CORT dated on 2018-05-31: Benzinga's Top Upgrades, Downgrades For May 31, 2018

Financial news for CORT dated on 2018-05-31: Stifel Nicolaus Downgrades Corcept Therapeutics to Hold

Financial news for CORT dated on 2018-05-17: UPDATE: FDA Offers Guidelines, Background For Reference Listed Drug Access Inquiries, Related To Claim Of Blocking Generic Rivals

Financial news for CORT dated on 2018-05-17: FDA Commissioner Scot Gottlieb Highlights List Of Cos. Which Have Potentially Blocked Access To Samples Of Their Branded Products: Pfizer, Biogen, INSYS, VIVUS, Valeant, Corcept Therapeutics

Financial news for CORT dated on 2018-05-08: Corcept Therapeutics Q1 EPS \$0.19 Beats \$0.16 Estimate, Sales \$57.7M Miss \$58.82M Estimate

Financial news for CORT dated on 2018-04-23: 24 Stocks Moving In Monday's Pre-Market Session

Financial news for CORT dated on 2018-03-15: Corcept Therapeutics Files Lawsuit Against Teva Pharmaceuticals for Infringement of Korlym Patents

Financial news for CORT dated on 2018-03-09: B. Riley Initiates Coverage On Corcept Therapeutics with Buy Rating, Announces \$30.00 Price Target

Financial news for CORT dated on 2018-02-22: Corcept Therapeutics Reports Q4 GAAP EPS \$0.77 vs \$0.04 In Same Qtr. Last Year, Sales \$55.3M vs \$53.7M Est.

Financial news for CORT dated on 2018-02-06: 33 Biggest Movers From Yesterday

Financial news for CORT dated on 2018-02-05: 31 Stocks Moving In Monday's Mid-Day Session

Financial news for CORT dated on 2018-02-05: Mid-Day Market Update: Dow Falls Over 250 Points; Enphase Energy Shares Spike Higher

Financial news for CORT dated on 2018-02-05: Mid-Morning Market Update: Markets Open Lower; Bristol-Myers Profit Tops Expectations

Financial news for CORT dated on 2018-02-02: Corcept Therapeutics Option Alert: Aug 17 \$26 Calls Sweep (13) at the Bid: 611 @ \$4.101 vs 25 OI; Earnings 4/30 After Close [est] Ref=\$24.11

Financial news for CORT dated on 2018-02-02: 44 Biggest Movers From Yesterday

Financial news for CORT dated on 2018-02-01: 38 Stocks Moving In Thursday's Mid-Day Session

Financial news for CORT dated on 2018-02-01: Corcept Therapeutics Reports Prelim. Q4 Sales \$53.3M vs \$53.9M Est.; FY17 Sales \$159.2M vs \$159.8M Est.

Financial news for CORT dated on 2017-12-22: Jim Cramer Gives His Opinion On Alphabet, Switch, And More

Financial news for CORT dated on 2017-12-22: 38 Biggest Movers From Yesterday

Financial news for CORT dated on 2017-12-21: Corcept Therapeutics Shares Up 13.8% On More Than 2x Avg. Volume, Watch For Shares To Test Near-Term Resistance Around \$18.50 Level

Financial news for CORT dated on 2017-12-21: 36 Stocks Moving In Thursday's Mid-Day Session

Financial news for CORT dated on 2017-12-20: S&P Dow Jones Indices Announces 'Interactive Brokers Group Set to Join S&P MidCap 400; Alarm.com Holdings and Corcept Therapeutics to Join S&P SmallCap 600'

Financial news for CORT dated on 2017-12-18: 31 Stocks Moving In Monday's Pre-Market Session

Financial news for CORT dated on 2017-12-06: 2 Reasons Why Cantor Fitzgerald Is Bullish on Strongbridge Biopharma

Financial news for CORT dated on 2017-11-02: Corcept Therapeutics Reports Q3 EPS \$0.11 vs \$0.14 Est., Sales \$42.8M vs \$42.03M Est.

Financial news for CORT dated on 2017-10-10: Weakness In Corcept Shares Is 'Overdone,' According To Analyst

Financial news for CORT dated on 2017-10-10: Corcept Shares Tick Slightly Higher Over Last Min. As Hearing Stifel Out Defending Against Downside

Financial news for CORT dated on 2017-10-10: Corcept Therapeutics Shares Have Moved 6.8% Lower Within 10 Minutes

Financial news for CORT dated on 2017-10-10: Mid-Morning Market Update: Markets Open Higher; Wal-Mart Reports \$20B Buyback Plan

Financial news for CORT dated on 2017-08-31: Stifel Nicolaus Initiates Coverage On Corcept Therapeutics with Buy Rating, Announces \$20.00 Price Target

Financial news for CORT dated on 2017-08-30: UPDATE: Corcept Says 'does not believe termination of the Dohmen Agreement will materially affect its operations or financial results for 2017 or beyond'

Financial news for CORT dated on 2017-08-30: UPDATE: Corcept Therapeutics Says 'Immediately following Dohmen's cessation of services under the Dohmen Agreement, Corcept began serving Korlym (R) patients through another specialty pharmacy, Optime Care'

Financial news for CORT dated on 2017-08-30: UPDATE: Corcept Filed Motion To Dismiss Dohmen Complaint

Financial news for CORT dated on 2017-08-30: 8-K From Corcept Therapeutics Shows Co. Filed Complaint Against Dohmen In Delaware Court, Alleging 'fraudulent inducement, negligent misrepresentation, breach of contract, breach of the covenant of good faith and fair dealing and conversion....'

Financial news for CORT dated on 2017-08-29: Jim Cramer Gives His Opinion On First Solar, Apache And More

Financial news for CORT dated on 2017-08-02: 18 Biggest Mid-Day Gainers For Wednesday

Financial news for CORT dated on 2017-08-01: Corcept Therapeutics Reports Q2 EPS \$0.13 vs. \$0.07 Est., Sales \$35.6M vs. \$32.53M Est.

Financial news for CORT dated on 2017-05-01: Corcept Therapeutics Reports Q1 Adj. EPS \$0.06 vs \$0.03 Est., Sales \$27.6M vs \$25.53M Est.

Financial news for CORT dated on 2017-03-13: Concept Therapeutics Files For \$200M Mixed Shelf Offering

Financial news for CORT dated on 2017-03-06: UPDATE: Corcept Raises FY17 Sales Outlook from \$115M-\$125M to \$120M-\$130M vs \$121.4M Est.

Financial news for CORT dated on 2017-03-06: Corcept Raises FY17 Sales Outlook

Financial news for CORT dated on 2017-03-06: Corcept Therapeutics Reports Q4 Adj. Net Income \$6.9M vs \$3.1M in Same Qtr. Last Year, GAAP EPS \$0.04 vs \$0.01 YoY, Sales \$23.8M, Inline

Financial news for CORT dated on 2017-02-02: Ladenburg On Biotech: Starts Achillion, Alnylam, Corcept, Trevana At Buy

Financial news for CORT dated on 2017-02-02: Ladenburg Thalmann Initiates Coverage On Corcept Therapeutics At Buy, Announces \$14 Price Target

Financial news for CORT dated on 2017-02-02: Ladenburg Thalmann Initiates Coverage On Corcept Therapeutics at Buy, Announces \$14.00 Target

Financial news for CORT dated on 2017-01-30: UPDATE: Corcept Sees FY17 Sales \$115M-\$125M vs \$124M Est.

Financial news for CORT dated on 2017-01-30: UPDATE: Corcept Reports Prelim. FY16 Sales \$81.3M vs \$81M Est.

Financial news for CORT dated on 2017-01-30: UPDATE: Corcept Reports Prelim. Q4 GAAP EPS \$0.04, Sales \$23.8M vs \$23.5M Est.

Financial news for CORT dated on 2017-01-30: Corcept Therapeutics Reports Prelim Q4, FY16 Results; Offers FY17 Outlook

Financial news for CORT dated on 2017-01-30: Corcept Therapeutics Expected To Hold Guidance Call This Morning

Financial news for CORT dated on 2017-01-23: Corcept Therapeutics Says Will Offer Prelim. FY16, FY17 Guidance on Jan. 30

Financial news for CORT dated on 2016-12-20: Mid-Day Market Update: Conatus Jumps Following Announcement of Licensing Deal With Novartis; Sucampo Shares Slide

Financial news for CORT dated on 2016-12-10: Corcept Therapeutics Announces Encouraging Results of Phase 1/2 Trial of Mifepristone Plus Eribulin in Triple-Negative Breast Cancer at 2016 San Antonio Breast Cancer Symposium

Financial news for CORT dated on 2016-12-07: San Antonio Breast Cancer Symposium (SABCS) Continues Today

Financial news for CORT dated on 2016-11-01: Corcept Therapeutics Reports Q3 non-GAAP EPS \$0.04, GAAP EPS \$0.02 vs \$0.01 Est, Revenue \$21.7M vs \$21.24M Est

Financial news for CORT dated on 2016-08-02: Corcept Therapeutics Reports Q2 EPS \$0.03 vs. Est. \$0.01, Rev. \$19.7M vs. Est. \$18.36M

Financial news for CORTEC dated on 2016-06-02: UPDATE: Corcept Says 'First patient enrolled in Phase 1/2 trial of selective cortisol modulator CORTEC125134 plus nab-paclitaxel (Celgene's Abraxane(r)) to treat a range of solid-tumor cancers'

Financial news for CORTEC dated on 2016-06-02: UPDATE: Corcept Says 'Preliminary efficacy results in Phase 1/2 trial of mifepristone plus eribulin (Eisai's Halaven(r)) to treat TNBC indicate combination is active; final results expected in mid-'16'

Financial news for CORTEC dated on 2016-06-02: Corcept Offers Update on Progress in Cortisol Modulation Oncology Program

Financial news for CORTEC dated on 2016-05-03: Corcept Therapeutics Reports Q1 \$0.02 Vs Est \$0.01, Sales \$16.061M Vs Est \$16.32M

Financial news for CORTEC dated on 2016-04-28: Corcept Therapeutics Releases Promising Pre-Clinical Data And Has Begun Recruiting Patients For Phase 1/2 Trial Of CORTEC125134

Financial news for CORTEC dated on 2016-03-01: Corcept Therapeutics Reaffirms FY16 Sales Outlook of \$76M-\$81M vs \$78.6M Est.

Financial news for CORTEC dated on 2016-03-01: Corcept Therapeutics Reports Q4 GAAP EPS \$0.01 vs \$(0.01) Est., Sales \$15M vs \$17.2M Est.

Financial news for CORTEC dated on 2016-01-28: Corcept Therapeutics Sees FY 2015 GAAP EPS \$(0.06) Vs Est \$(0.09), Revs \$50.3M Vs Est \$50.94M

Financial news for CORTEC dated on 2016-01-21: Corcept Therapeutics Says Will Give Prelim. FY15, FY16 Outlook on Jan. 28, '16

Financial news for CORTEC dated on 2015-12-24: Mid-Morning Market Update: Markets Edge Lower; Cal-Maine Misses Q2 Expectations

Financial news for CORTEC dated on 2015-12-14: Corcept Therapeutics Reports First Efficacy Results in Phase 1/2 Trial of Mifepristone in Combination With Eribulin for the Treatment of Patients With Metastatic Triple-Negative Breast Cancer

Financial news for CORTEC dated on 2015-11-05: Corcept Therapeutics Reports Q3 EPS \$(0.01) vs \$(0.02) Est., Sales \$13.3M vs \$14M Est.; Sees FY15 Sales \$49M-\$53M vs \$52.1M Est.

Financial news for CORTEC dated on 2015-10-13: UPDATE: Corcept Therapeutics to Commence Separation of Phase 2 Trials of CORTEC125134 in Q1'16

Financial news for CORTEC dated on 2015-10-13: Results of Phase 1 Trial of Next-Generation Cortisol Modulator CORTEC125134 to Be Presented at Annual Meeting of the American Association of Pharmaceutical Scientists

Financial news for CORTEC dated on 2015-09-28: Corcept Therapeutics Names Dr. Robert Fishman Chief Medical Officer

Financial news for CORTEC dated on 2015-08-18: Option Alert: Cortis Therapeutics Aug \$6 Call; 564 Contracts vs 536 OI; Now \$5.41

Financial news for CORTEC dated on 2015-08-05: Corcept Therapeutics Reports Q2 EPS \$(0.02) vs. Est. \$(0.04), Rev. \$12M vs. Est. \$11.67M

Financial news for CORTEC dated on 2015-07-21: Mid-Day Market Update: Dow Dips Over 1%; Harley-Davidson Shares Rise On Earnings Beat

Financial news for CORTEC dated on 2015-05-07: Corecept Reports Q1 Loss \$0.05 Vs Est Loss \$0.04, Sales \$10.1M Vs Est \$10.51M

Financial news for CORTEC dated on 2015-04-21: Benzinga's Top Initiations

Financial news for CORTEC dated on 2015-04-21: FBR Capital Initiates Coverage on Corcept Therapeutics at Outperform, Announces \$12.00 PT

Financial news for CORTEC dated on 2015-04-01: Warrant Exercises Generate \$17.2M; Proceeds to Advance Next-Generation Compounds and Support Commercialization of Korlym

Financial news for CORTEC dated on 2015-03-30: 5 NASDAQ Healthcare Stocks With The Highest EPS Growth Forecast For Next 5 Years

Financial news for CORTEC dated on 2015-03-11: Piper Jaffray Upgrades Corcept Therapeutics to Overweight, Raises PT to \$9.00

Financial news for CORTEC dated on 2015-03-04: Corcept Therapeutics Reports Q4 Adj.

Loss of \$0.02/Share vs Loss of \$0.06/Share Est.

Financial news for CORTE dated on 2014-11-04: Corcept Therapeutics Incorporated Cuts FY2014 Sales To \$25.0M-27.0M

Financial news for CORTE dated on 2014-08-05: Corcept Therapeutics Incorporated Sees FY2014 Sales \$25.0M-29.0M

Financial news for CORTE dated on 2014-08-05: Corcept Therapeutics Incorporated Reports Q2 EPS of \$(0.05) vs \$(0.10) Est; Revenue of \$5.85M vs \$6.0M Est

Financial news for CORTE dated on 2014-06-12: Corcept Therapeutics Director Baker Jr Buys 103,386 Shares @\$2.32/Share -Form 4

Financial news for CORTE dated on 2014-05-07: Morning Market Losers

Financial news for CORTE dated on 2014-05-07: Corcept Therapeutics Resumes Trading Down 50% Following Earnings Miss, Trial Halt

Financial news for CORTE dated on 2014-05-07: Shares of Corcept to Resume Trade at 9AM EDT

Financial news for CORTE dated on 2014-05-07: From Corcept Earnings Press Release: Shows Mifepristone Trial Has Failed to Show Efficacy

Financial news for CORTE dated on 2014-05-07: Corcept Therapeutics Incorporated Reports Q1 EPS of \$(0.11) vs \$(0.09) Est; Product Revenue of \$4.40M vs \$5.01M Est

Financial news for CORTE dated on 2014-05-07: Corcept Therapeutics Shares Halted News Pending

Financial news for CORTE dated on 2014-04-17: Option Alert: Corcept Therapeutics May \$4 Call; 2,546 Contracts Traded vs 1,836 OI; Currently \$3.82

Financial news for CORTE dated on 2014-04-01: Brinson Patrick Initiates Coverage on Corcept Therapeutics Incorporated at Market Outperform, Announces \$8.00 PT

Financial news for CORTE dated on 2014-03-10: UPDATE: Stifel Terminates Coverage on Corcept Therapeutics Due to Reallocation of Resources

Financial news for CORTE dated on 2014-01-13: UPDATE: Stifel Downgrades Corcept Therapeutics, See Gradual Progress with Korlym

Financial news for CORTE dated on 2014-01-13: Stifel Nicolaus Downgrades Corcept Therapeutics Incorporated to Hold, Removes \$3.00 PT

Financial news for CORTE dated on 2013-11-07: Corcept Therapeutics Incorporated Reports Q3 EPS of \$(0.08) vs \$(0.12) Est

Financial news for CORTE dated on 2013-08-09: Janney Capital Downgrades Corcept Therapeutics to Neutral, Lowers PT to \$2.00

Financial news for CORTE dated on 2013-08-09: Credit Suisse Downgrades Corcept Therapeutics Incorporated to Neutral, Lowers PT to \$2.00

Financial news for CORTE dated on 2013-08-08: Corcept Therapeutics Incorporated Reports Q2 EPS of \$(0.10) vs \$(0.11) Est; Revenue of \$1.89M vs \$2.72M Est

Financial news for CORTE dated on 2013-05-06: UPDATE: Piper Jaffray Downgrades Corcept Therapeutics to Neutral Following 1Q13 Earnings Report

Financial news for CORTE dated on 2013-05-06: Piper Jaffray Downgrades Corcept Therapeutics Incorporated to Neutral, Lowers PT to \$2.00

Financial news for CORTE dated on 2013-05-02: Corcept Therapeutics Incorporated Reports Q1 EPS of \$(0.10) vs \$(0.09) Est

Financial news for CORTE dated on 2013-03-07: Corcept Therapeutics Incorporated Reports Q4 EPS of \$(0.09), Inline

Financial news for CORTE dated on 2013-01-02: Janney Capital Initiates Coverage on Corcept Therapeutics Incorporated at Buy, Announces \$3.00 PT

Financial news for CORTE dated on 2012-12-10: From Earlier: Cowen & Company Downgrades Corcept Therapeutics Incorporated to Neutral

Financial news for CORTE dated on 2012-11-13: Credit Suisse Reinstates Coverage on Corcept Therapeutics at Outperform, Lowers PT from \$6 to \$4



Financial news for CORTEC dated on 2012-11-08: UPDATE: Piper Jaffray Downgrades Corcept Therapeutics to Underweight on Competitive Concerns

Financial news for CORTEC dated on 2012-11-08: Piper Jaffray Downgrades Corcept Therapeutics from Neutral to Underweight, Lowers PT from \$3 to \$1.10

Financial news for CORTEC dated on 2012-11-02: UPDATE: Oppenheimer Downgrades Corcept Therapeutics to Perform on Disappointing Sales

Financial news for CORTEC dated on 2012-11-02: Oppenheimer Downgraded Corcept Therapeutics from Outperform to Market Perform

Financial news for CORTEC dated on 2012-11-01: Bank of America Maintains Corcept Therapeutics at Underperform, Lowers PO from \$4 to \$2

Financial news for CORTEC dated on 2012-10-15: Corcept Therapeutics Appoints Daniel M. Bradbury to Board of Directors

Financial news for CORTEC dated on 2012-09-13: UPDATE: Piper Jaffray Downgrades Corcept Therapeutics to Neutral on Korlym Outlook

Financial news for CORTEC dated on 2012-09-13: Piper Jaffray Downgrades Corcept Therapeutics from Overweight to Neutral, Lowers PT from \$5 to \$3

Financial news for CORTEC dated on 2012-08-07: Oppenheimer Maintains Corcept Therapeutics at Outperform, Raises PT from \$6 to \$7

Financial news for CORTEC dated on 2012-08-07: Corcept Therapeutics Reports Q2 EPS \$-0.09 vs \$-0.11 Est

Financial news for CORTEC dated on 2012-08-07: Corcept Therapeutics Halted for News

Financial news for CORTEC dated on 2012-07-24: UPDATE: Oppenheimer Lowers PT on Corcept Therapeutics from \$9 to \$8

Financial news for CORTEC dated on 2012-07-24: Oppenheimer Maintains Corcept Therapeutics at Outperform, Lowers PT from \$9 to \$8

Financial news for CORTEC dated on 2012-07-13: Equity Moves on Sell-Side Sentiment for July 13, 2012

Financial news for CORTEC dated on 2012-07-13: UPDATE: Bank of America Initiates Corcept Therapeutics at Underperform on Korlym Launch Caution

Financial news for CORTEC dated on 2012-07-13: Bank of America Initiates Coverage on Corcept Therapeutics at Underperform, Announces PO of \$4

Financial news for CORTEC dated on 2012-07-02: Corcept Therapeutics Announces Underwritten Public Offering of 11M Shares

Financial news for CORTEC dated on 2012-07-02: Corcept Therapeutics Commences Public Offering of 11M Shares

Financial news for CORTEC dated on 2012-06-29: ThinkEquity Initiates Coverage On Corcept Therapeutics at Buy

Financial news for CORTEC dated on 2012-04-10: Ladenburg Thalmann: Corcept Therapeutics SEISMIC Article

Financial news for CORTEC dated on 2012-04-09: Corcept Therapeutics Says Data Shows Clinical Improvement

Financial news for CORTEC dated on 2012-04-09: Corcept Therapeutics Trading 2% Higher on Heavy Volume; Currently at \$4.04

Financial news for CORTEC dated on 2012-03-26: Corcept Says Investors Exercised Warrants to Buy 4.2M Shares

Financial news for CORTEC dated on 2012-03-26: Corcept Therapeutics Announces Exercise of Warrants and Private Placement of New Warrants

Financial news for CORTEC dated on 2012-03-05: Corcept to Introduce Korlym by May 1st, 2012

Financial news for CORTEC dated on 2012-02-22: Corcept Therapeutics: One and Done or More to Come?

Financial news for CORTEC dated on 2012-02-21: Corcept Analyst: US Sales of Cushing Syndrome Drug Korlym Could Reach \$200M/Year

Financial news for CORT dated on 2012-02-21: UPDATE: Stifel Nicolaus Increases Target to \$9 on Corcept Therapeutics

Financial news for CORT dated on 2012-02-21: Corcept Therapeutics Pops 61% After Friday's FDA Approval

Financial news for CORT dated on 2012-02-21: Stifel Nicolaus Maintains Corcept Therapeutics at Buy, Raises PT from \$7 to \$9

Financial news for CORT dated on 2012-02-21: Corcept Therapeutics Rises 60% on Friday's FDA Approval for Korlym

Financial news for CORT dated on 2012-02-17: PREVIEW: Corcept Therapeutics to Resume Trading at 6:40pm

Financial news for CORT dated on 2012-02-17: Corcept Therapeutics Receives FDA Approval for Korlym

Financial news for CORT dated on 2012-02-17: Corcept Therapeutics Halted; Wins FDA Approval on its Korlym Drug

Financial news for CORT dated on 2012-02-16: Reminder: Corcept Therapeutics Has Their PDUFA Date Tomorrow

Financial news for CORT dated on 2012-01-31: Notable Call Options Activity in Corcept Therapeutics

Financial news for CORT dated on 2012-01-16: Will Korlym Relieve Your Portfolio's Stress?

Financial news for CORT dated on 2012-01-05: Notable Put Options Activity in Corcept Therapeutics

Financial news for CORT dated on 2011-12-15: Corcept's FDA Submission Will Not Require a Risk Evaluation and Mitigation Strategy

Financial news for CORT dated on 2011-11-28: Oppenheimer Names Corcept Therapeutics on December's Top Ideas

Financial news for CORT dated on 2011-11-10: Ladenburg Thalmann Maintains Buy, PT on Corcept Therapeutics

Financial news for CORT dated on 2011-09-26: Oppenheimer Maintains Outperform Rating on Corcept Therapeutics

Financial news for CORT dated on 2011-08-22: Corcept Announces No FDA Advisory Committee Meeting Planned in Connection With New Drug Application for CORLUX for Cushing's Syndrome

Financial news for CORT dated on 2011-08-22: Gary C. Robb Joins Corcept as Chief Financial Officer

Financial news for CORT dated on 2011-08-09: McNicoll, Lewis & Vlask Reiterates Corcept Therapeutics Buy, \$8 PT

Financial news for CORT dated on 2011-08-05: UPDATE: Oppenheimer Initiates Coverage on Corcept Technologies

Financial news for CORT dated on 2011-08-05: Oppenheimer Initiates Corcept Therapeutics At Outperform, \$8 PT

Financial news for CORT dated on 2011-06-30: FDA Accepts Submission of New Drug Application for CORLUX for Cushing's Syndrome

Financial news for CORT dated on 2011-06-07: Piper Jaffray Raises PT On Corcept Therapeutics To \$7

Financial news for CORT dated on 2011-06-06: UPDATE: Piper Jaffray Raises PT on Corcept Therapeutics to \$7

Financial news for CORT dated on 2011-06-06: Piper Jaffray Raises PT On Corcept Therapeutics To \$7

Financial news for CORT dated on 2011-04-15: Corcept Therapeutics Announces NDA Submitted to the FDA for the Use of CORLUX in Cushing's Syndrome

Financial news for CORT dated on 2011-04-01: Global Hunter Comments On Corcept's Corlux NDA Submission During Week Of April 11

Financial news for CORT dated on 2011-04-01: Piper Jaffray Comments On Corlux NDA Announcement (CORT)

Financial news for CORT dated on 2011-03-31: Corcept Therapeutics Announces NDA Submission to Be Completed the Week of April 11

Financial news for CORT dated on 2011-03-10: Piper Jaffray Reduces Corcept Therapeutics PT From \$7.40 (CORT)

Financial news for CORT dated on 2011-01-11: Piper Jaffray Remains OW On Corcept Therapeutics Following Corlux Data

Financial news for CORT dated on 2010-12-22: Corcept Therapeutics Slightly Up After FDA News (CORT)

Financial news for CORT dated on 2010-12-22: Corcept Therapeutics Hormone Drug Meets Main Trial Goal (CORT)

Financial news for CORT dated on 2010-11-30: Biotech Calendar: Key Dates for December

Financial news for CORT dated on 2010-05-05: Stocks That Created New 52-Week Highs (AKRX, AMMD, ATRO, CSTR, CORT)

Financial news for CORT dated on 2010-05-04: CORT Initiated With Outperform At JMP Securities